CHRONIC HEPATITIS B

This study tests a new two-drug combination (ASC22 and Peg-IFNa) to see if it can functionally cure chronic hepatitis B. About 150 adults with low virus levels will receive the treatment. The goal is to raise the cure rate above 50% without needing lifelong medication.

This trial tests whether giving the antiviral drug tenofovir disoproxil fumarate (TDF) to pregnant women with active hepatitis B can prevent the virus from spreading to their babies. The women take TDF from the 28th week of pregnancy until six weeks after giving birth, and all ne…

This early-stage trial tests a new therapy called CRMA-1001, which uses epigenetic gene silencing to turn off the hepatitis B virus in the body. About 66 adults with chronic hepatitis B who are already on antiviral pills will receive one or more IV infusions of the therapy. The m…

This study tests a therapeutic vaccine called TherVacB in 81 adults with chronic hepatitis B who are already on antiviral medication. The vaccine is given as a series of shots to boost the immune system and lower hepatitis B virus levels. The main goals are to check safety and se…

This early-stage study tests an injection called AHB-171 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it shows any signs of controlling the virus. About 110 participants will be enrolle…

This study tests two drugs, VIR-2218 and peginterferon, in 50 adults with mild chronic hepatitis B. The goal is to lower the virus level in the blood and improve the body's immune response. Participants receive injections for 6 months and are followed for over 2 years, including …

This early-stage trial tests a lab-made antibody (HepB mAb19) in 15 people with chronic hepatitis D, a serious liver infection that requires hepatitis B to survive. The goal is to see if the antibody is safe and can lower virus levels, potentially reducing the risk of liver damag…

This Phase 2 trial tests a new drug called AHB-137, given alongside a hepatitis B vaccine or peginterferon, in 200 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the combination can clear the hepatitis B surface antigen (HBsAg) from the …

This study tests whether a mobile app called HBVCare can help people with chronic hepatitis B take their medication regularly and attend follow-up visits. About 70 adults in Vietnam will either use the app or receive standard care. After 3 months, researchers will compare how wel…

This study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. About 200 adults who already responded to AHB-137 will be followed for years. The goal is to see if the virus stays undetectable and if liver health improves witho…

This Phase 2 trial tests an injection called AHB-137 in 60 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the drug can lower virus levels enough that patients can safely stop all treatment. The study will check if the virus stays undetec…

This study involves over 16,000 people with chronic hepatitis B across three hospitals. The goal is to increase the number of patients referred to liver specialists and started on antiviral treatment. Researchers will also track how antiviral therapy affects patients' quality of …

This 5-year study tests whether dapagliflozin, a diabetes drug, can prevent serious liver complications in people with chronic hepatitis B and diabetes who already have early liver scarring. 412 participants will receive either dapagliflozin or a placebo daily. The goal is to see…

This Phase 3 trial tests whether adding GST-HG141 (Neracorvir) to standard antiviral therapy can better suppress the hepatitis B virus in patients who haven't responded adequately to current drugs. About 526 adults with chronic hepatitis B will receive either the experimental dru…

This study tests whether hepatitis B immunoglobulin (HBIG) can help people with chronic hepatitis B stay virus-free after they've cleared the surface antigen (a key sign of cure). Researchers will give HBIG shots to 132 participants who already cleared the virus with standard the…

This early-stage study tests the safety of a new drug, Tune-401, in 36 adults with chronic hepatitis B. Participants must already be on standard antiviral medication. The goal is to see if Tune-401 is safe and how the body processes it, not yet to cure the infection.

This phase 3 study tests azvudine tablets in 120 people with chronic hepatitis B. The drug works by both fighting the virus and activating the immune system. Researchers will monitor viral load, liver function, and immune activity over 12 months to see if azvudine can help achiev…

This early-stage study tests a new medicine called SA1211 for chronic hepatitis B, a long-term liver infection. Researchers will check safety and how the body processes the drug in 80 healthy volunteers and people with hepatitis B. The goal is to see if it can help control the vi…

This study looks at whether taking a specific gut bacterium (Bacteroides fragilis) along with branched-chain amino acids can help clear the hepatitis B virus in people with chronic infection. About 40 participants will receive this combo as an add-on to their usual antiviral trea…

This study tests an experimental drug called HRS-5635, given alone or with other medications, in people with chronic hepatitis B. The goal is to lower or clear the hepatitis B surface antigen (HBsAg) from the blood, which could mean better long-term control of the virus. About 36…

This Phase 2 trial is testing an experimental drug called F573 in 97 people with acute liver failure or acute-on-chronic liver failure. Participants receive daily injections of F573 or a placebo for 7 days. The main goal is to check safety and side effects, while also looking at …

This early study is testing whether HEPLISAV-B, a vaccine normally used to prevent hepatitis B, is safe for people who already have chronic hepatitis B. Ten adults on stable antiviral therapy will receive two vaccine shots and be monitored for side effects and immune responses ov…

This study tests a new medicine, LW231, in people with chronic hepatitis B. The goal is to see if it is safe and can lower the amount of virus in the blood. Some participants will get LW231 alone, others will get it together with standard antiviral pills. The trial involves about…

This early-stage study tests a new gene therapy called PBGENE-HBV in 45 adults with chronic hepatitis B who are already on antiviral medication. The goal is to see if the treatment is safe and can help control the virus. Participants must be in good health and have no liver scarr…

This phase 2 trial tests a combination of an anti-PD-1 antibody, interferon, and standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to boost the immune system to clear the virus and achieve a functional cure, where the virus stays under control without l…

This pilot study tests a drug called Imdusiran (AB-729) in 10 people with chronic hepatitis B. Participants receive four injections over 24 weeks and undergo two liver biopsies to measure how the drug works inside the liver and how it affects the virus. The goal is to understand …

This phase 2 trial tests a new combination of an anti-PD-1 antibody (a type of immunotherapy) plus standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to achieve a functional cure, where the virus is no longer active and patients can stop medication. The …

This study is testing a drug called TAF (tenofovir alafenamide) in pregnant women with chronic hepatitis B. The goal is to see if taking TAF daily from week 28-32 of pregnancy until delivery can prevent the baby from catching the virus. Researchers will also check how the drug mo…

This study looks at whether magnetic resonance elastography (MRE), a special type of MRI, can accurately measure liver scarring (fibrosis) in people with chronic hepatitis B. Researchers will compare MRE results to standard liver biopsies in 600 adults. If MRE works well, it coul…

This study aims to find out how often people with chronic hepatitis B also have hepatitis D, and which types of the virus are most common. Researchers will interview about 2,400 participants and take blood samples to look for links with vaccination history, lifestyle, and other f…

This study looks at genetic changes in natural killer (NK) and B cells—key immune cells—in people with chronic hepatitis B. Researchers want to understand why these cells don't work properly during long-term infection. The study will analyze blood samples from 140 adults with chr…

This study looks at whether people with chronic hepatitis B who have undetectable virus levels in their blood also have undetectable levels in other body fluids like saliva or semen. Researchers will compare treated patients with suppressed virus to untreated patients with active…

This study looks at why the hepatitis B virus (HBV) stays in the liver for so long, even with treatment. Researchers will use a gentle needle technique to take small liver samples from 100 adults with chronic HBV. They want to see how the virus and the immune system interact insi…

This study looks at the link between gum (periodontal) disease and hepatitis B+D infection, and whether the drug bulevirtide changes that relationship. Researchers will measure inflammation markers in saliva and gum fluid from 25 adults: those with hepatitis B+D on bulevirtide, t…

This study follows 33,000 adults with chronic hepatitis B to see how well different antiviral medicines work over up to 5 years. Researchers will compare treatments like entecavir, tenofovir, and peginterferon to find which ones best prevent liver cancer and other serious liver p…

This real-world study is following 15,000 people with chronic hepatitis B across 200 hospitals in China. Researchers are comparing how well different antiviral drugs and interferon injections work to prevent liver cancer and improve long-term health. The goal is to find the best …